New inhaler combo aims to tame dangerous lung pressure
Disease control
Recruiting now
This study is testing the safety of a new inhaled drug, mosliciguat, when added to an existing inhaled medication (treprostinil) for people with pulmonary hypertension caused by scarred lungs (interstitial lung disease). It will enroll about 20 participants who are already using …
Phase: PHASE2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC